Medicilon's pharmacology models for inflammatory-immune diseases

Inflammatory immune diseases have gained much attention as the incidence has grown bigger each year. The diseases can affect many parts of human bodies and reduce the quality of life drastically. Yet the diagnoses can be frustrating and stressful because no one is sure what causes such diseases.

The preclinical pharmacology department of Medicilon has been deeply involved in this field for many years, and has provided a variety of stable and reliable animal models for different targets and pathways for the evaluation of inflammatory immune disease treatments in order for the successful clinical transformation.

❖ Medicilon's Inflammatory & Immune Diseases Models

At present, as the pathogenesis of inflammatory and immunological diseases is unclear, there are few effective therapeutic drugs available in clinical practice. In such a context, the appropriate preclinical research techniques and models are required to help companies and researchers further develop and evaluate new drugs. Our Preclinical Pharmacodynamics Department has been deeply involved in this field for years, developing reliable animal-based efficacy evaluation models aimed at different targets and pathways, thus facilitating the clinical transformation of new drugs.

RA, rheumatoid arthritis

RA is a chronic and systemic inflammatory autoimmune disease mainly targeting joints. It has a very high disability rate. The cause of the disease is still unclear.

Medicilon models that you can choose from:

CIA mice/rats Models
CFA rats Models

Major Endpoints

Foot Volume

△CIA Models △CFA Models

Arthritis Index

△CIA Models

Cytokine Expression

△CFA Models

Other arthritis models:

Carrageenan-induced acute arthritis mice/rats models

Uric acid sodium induced gouty arthritis rats models

"Leaky Gut" with Age Improved through Dietary Restriction

Altered Levels of Neonatal Inflammatory Markers Associated with Childhood Leukemia

Key Protein Mediating Inflammatory Response Discovered

EAE, experimental allergic encephalomyelitis

Psoriasis

Psoriasis is a common skin disease that occurs worldwide. It is a disease that is not only closely related to genetics, but also obviously related to the environment.

Medicilon establishes diverse models that captures key features of psoriasis, including:

IL-23 induced hyperplasia of auricle epidermis mice models
Imiquimod induced psoriasis mice models
Vaginal epithelial mitosis mice models
Tale exfoliation mice models

Major Endpoints:

Skin thickness

△Pathological skin change of Imiquimod induced psoriasis mice

Ear thickness

△Pathological skin change of IL-23 induced psoriasis mice

Skin colligation score of mice

△Pathological skin change of Imiquimod induced psoriasis mice

Pathological skin score

△Imiquimod induced psoriasis △IL-23 induced psoriasis

AD, atopic dermatitis

Atopic dermatitis is a chronic, recurring, inflammatory skin disease, often accompanied by other symptoms such as allergic rhinitis, asthma, eczema, etc. The cause of the disease is not yet clear and there is no cure.

The disease related models include:

DNFB induced chronic dermatitis mice models
DNFB & OX induced chronic dermatitis mice models
Phorbol ester induced acute eczema mice models
DNFB induced acute eczema mice models

Skin score

△DNFB induced chronic dermatitis

Skin thickness

△DNFB induced chronic dermatitis

IBD, Infectious Bursal Disease

Inflammatory bowel disease (IBD) is a group of unexplained chronic intestinal inflammatory diseases. Due to the increasing incidence, it has become a common digestive system disease in our country. It mainly refers to ulcerative colitis and Crohn’s Disease.

Our IBD models includes:

TNBS induced IBD rats models

DSS induced IBD mice models

△Colon length of TNBS induced IBD rats models

△Colon weight of DSS induced IBD mice models

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客